SBR-001 is an “Add-on” combination therapy of two ROS modulating drugs together with standard-of-care (SoC) Temozolomide to treat Glioblastoma. Preclinical proof-of-concept was established in Orthotopic Glioma rat model with improved survival rate and elimination of cancer cells.